Basal cell carcinoma: Early Recognition, differential diagnosis, and treatment indication
International Health Sciences Review · 04.05.2026 · 2 (3)
DOI: 10.70164/ihsr.v2i3.172 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Health Sciences Review, online erschienen am 04.05.2026. Verfasst von Larissa Tatoni Rocha Hamamoto und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Basal cell carcinoma is the most common malignant neoplasm in humans and represents a relevant clinical burden due to its high incidence, association with ultraviolet radiation, potential for local invasion, and frequent diagnostic delay in early or atypical presentations. This narrative literature review aimed to provide a practical framework for early recognition, differential diagnosis, risk stratification, and treatment selection in basal cell carcinoma. Evidence was synthesized from relevant publications indexed in PubMed, SciELO, and the Cochrane Library, prioritizing clinical guidelines, systematic reviews, randomized trials, and dermatologic oncology studies addressing diagnosis, dermoscopy, histopathology, surgical management, and nonsurgical therapies. The findings indicate that persistent pearly papules, telangiectatic nodules, superficial erythematous plaques, recurrent erosions, pigmented lesions, and scar-like indurated plaques should raise clinical suspicion. Dermoscopy improves diagnostic accuracy by identifying arborizing telangiectasias, blue-gray ovoid nests, leaf-like areas, spoke-wheel structures, ulceration, shiny white structures, and short fine telangiectasias. Treatment selection should be guided by tumor location, size, borders, recurrence, immune status, perineural involvement, and histological subtype. Low-risk tumors may be managed with standard excision or selected nonsurgical therapies, whereas high-risk lesions require complete margin assessment, preferably Mohs micrographic surgery. Early diagnosis and individualized treatment are essential to reduce recurrence, functional impairment, aesthetic morbidity, and healthcare costs.
Zitieren
APA
Hamamoto, L. T. R., Camacho, L. F., Moraes, A. A. L. D., Souza, M. P. D., & Sanchez, E. P. (2026). Basal cell carcinoma: Early Recognition, differential diagnosis, and treatment indication. International Health Sciences Review, 2(3). https://doi.org/10.70164/ihsr.v2i3.172
Vancouver
Hamamoto LTR, Camacho LF, Moraes AALD, Souza MPD, Sanchez EP. Basal cell carcinoma: Early Recognition, differential diagnosis, and treatment indication. International Health Sciences Review. 2026;2(3). doi:10.70164/ihsr.v2i3.172
BibTeX
@article{Hamamoto2026,
author = {Hamamoto, Larissa Tatoni Rocha and Camacho, Lais Ferreira and Moraes, Aline Ayres Leme de and Souza, Mariana Paschoarelli de and Sanchez, Enrique Palmeira},
title = {Basal cell carcinoma: Early Recognition, differential diagnosis, and treatment indication},
journal = {International Health Sciences Review},
year = {2026},
volume = {2},
number = {3},
doi = {10.70164/ihsr.v2i3.172}
}
EUVIMED